Neuroendocrine prostate cancer or prostatitis? An unusual false positive on gallium-68 DOTA-Tyr3-octreotate positron emission tomography/computed tomography in a patient with known metastatic neuroendocrine tumor

Matthew Q Schmidt; Zachary Trenbeath; Bennett B Chin

doi:10.4103/wjnm.WJNM_11_19

World Journal of Nuclear Medicine, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · World J Nucl Med 2019; 18(03): 304-306
DOI: 10.4103/wjnm.WJNM_11_19

Case Report

Neuroendocrine prostate cancer or prostatitis? An unusual false positive on gallium-68 DOTA-Tyr3-octreotate positron emission tomography/computed tomography in a patient with known metastatic neuroendocrine tumor

Matthew Q Schmidt

Department of Internal Medicine, Saint Joseph Hospital, Denver, Colorado, USA

,

Zachary Trenbeath

¹Department of Radiology, Division of Nuclear Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA

,

Bennett B Chin

¹Department of Radiology, Division of Nuclear Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA

› Institutsangaben

Abstract

The importance of gallium-68 DOTA-Tyr3-octreotate (⁶⁸Ga DOTATATE) positron emission tomography/computed tomography (PET/CT) in the imaging of neuroendocrine tumors (NETs) has grown substantially over the past decade and is becoming markedly more common. We present the case of a male with known metastatic NET who underwent ⁶⁸Ga DOTATATE PET/CT for restaging, incidentally revealing intense uptake of the prostate with a maximum standard uptake value of 17.4. Due to the patient's medical history, this finding was concerning for neuroendocrine prostate cancer. However, core biopsies of the prostate were negative for malignancy and positive for chronic inflammation. Chronic prostatitis is a very common condition in adult males and is often asymptomatic. Inflammatory conditions, including prostatitis, are important causes of false-positive findings on ⁶⁸Ga DOTATATE PET/CT and should be considered as part of the differential diagnosis, even in an asymptomatic patient.

Keywords

False positive - gallium-68 DOTA-Tyr3-octreotate - neuroendocrine prostate cancer - neuroendocrine tumor - nuclear medicine - positron emission tomography/computed tomography - prostatitis

Volltext

Referenzen

References
1 Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, et al. Prospective study of 68Ga-DOTATATE positron emission tomography/Computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol 2016;34:588-96.
2 Zaffuto E, Pompe R, Zanaty M, Bondarenko HD, Leyh-Bannurah SR, Moschini M, et al. Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: A SEER database analysis. Clin Genitourin Cancer 2017;15:e793-800.
3 Marcus DM, Goodman M, Jani AB, Osunkoya AO, Rossi PJ. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis 2012;15:283-8.
4 DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014;64:252-71.
5 Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: Consensus report from the first national institutes of health international prostatitis collaborative network. Urology 1999;54:229-33.
6 Carver BS, Bozeman CB, Williams BJ, Venable DD. The prevalence of men with national institutes of health category IV prostatitis and association with serum prostate specific antigen. J Urol 2003;169:589-91.
7 Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: Clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 2015;35:500-16.
8 Subramaniam RM, Bradshaw ML, Lewis K, Pinho D, Shah C, Walker RC, et al. ACR practice parameter for the performance of gallium-68 DOTATATE PET/CT for neuroendocrine tumors. Clin Nucl Med 2018;43:899-908.
9 Moradi F, Jamali M, Barkhodari A, Schneider B, Chin F, Quon A, et al. Spectrum of 68Ga-DOTA TATE uptake in patients with neuroendocrine tumors. Clin Nucl Med 2016;41:e281-7.
10 Shastry M, Kayani I, Wild D, Caplin M, Visvikis D, Gacinovic S, et al. Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nucl Med Commun 2010;31:1025-32.